ArticleRisk management and healthcare policy2017
Economic burden of hospitalizations of Medicare beneficiaries with heart failure.
Article in Risk management and healthcare policy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05080504 (Heart Failure Monitoring With Eko Electronic Stethoscopes), which is not on this map. Cited by 84 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Heart Failure Monitoring With Eko Electronic Stethoscopes (CardioMEMS)
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Burden of hospitalization for heart failure in the United States: a systematic literature review.Journal of managed care & specialty pharmacy · 2022Pooled it
- Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.JAMA network open · 2022Pooled it
- A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020).PharmacoEconomics · 2020Pooled it
- Alert-driven vs scheduled remote monitoring of implantable cardiac defibrillators: A cost-consequence analysis from the TRUST trial.Heart rhythm · 2023Trial
- A Randomized Controlled Trial Comparing Telehealth Self-Management to Standard Outpatient Management in Underserved Black and Hispanic Patients Living with Heart Failure.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2019Trial
- Health care resource utilization and costs associated with obesity classes among patients with heart failure with preserved ejection fraction.International journal of cardiology. Heart & vasculature · 2026Article
- Experience and Outcomes of a Dedicated Cardio-Nephrology Service: A Step toward Integrated Cardiovascular-Kidney-Metabolic Syndrome Care.Kidney360 · 2026Observational
- Exploring the mechanism of Yi Qi Huo Xue compound prescription in treating chronic heart failure based on integrated network pharmacology and transcriptomics.Frontiers in cardiovascular medicine · 2026Article
- Long-Term Outcomes Following Catheter-Based Therapies in Older Adults With Acute Pulmonary Embolism.JACC. Advances · 2025Article
- Economic impact of sotagliflozin among patients with heart failure and type 2 diabetes: Budget impact analysis from the US payer perspective.Journal of managed care & specialty pharmacy · 2025Article
- Deep learning for predicting rehospitalization in acute heart failure: Model foundation and external validation.ESC heart failure · 2024Article
- Recent Advances in the Wearable Devices for Monitoring and Management of Heart Failure.Reviews in cardiovascular medicine · 2024Review
- Use of Palliative Care Among Adults With Newly Diagnosed Heart Failure: Insights From a US National Insured Patient Sample.Journal of the American Heart Association · 2024Article
- How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes.Journal of managed care & specialty pharmacy · 2024Article
- Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome.Advances in therapy · 2024Article
- Percutaneous Microaxial Ventricular Assist Device Versus Intra-Aortic Balloon Pump for Nonacute Myocardial Infarction Cardiogenic Shock.Journal of the American Heart Association · 2024Article
- Article
- Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure.Journal of comparative effectiveness research · 2024Article
- Article
- Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF Trials.Journal of the American Heart Association · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to assess the costs associated with the hospitalization and the cumulative 30-, 60-, and 90-day readmission rates in a cohort of Medicare beneficiaries with heart failure (HF).
methodsThis was a retrospective, observational study based on data from the national 5% sample of Medicare beneficiaries. Inpatient data were gathered for Medicare beneficiaries with at least one HF-related hospitalization between July 1, 2005, and December 31, 2011. The primary end point was the average per-patient cost of hospitalization for individuals with HF. Secondary end points included the cumulative rate of hospitalization, the average length of hospital stay, and the cumulative 30-, 60-, and 90-day readmission rates.
resultsData from 63,678 patients with a mean age of 81.8 years were included in the analysis. All costs were inflated to $2,015 based on the medical care component of the Consumer Price Index. The mean per-patient cost of an HF-related hospitalization was $14,631. The mean per-patient cost of a cardiovascular (CV)-related or all-cause hospitalization was $16,000 and $15,924, respectively. The cumulative rate of all-cause hospitalization was 218.8 admissions per 100 person-years, and the median length of stay for HF-related, CV-related, and all-cause hospitalizations was 5 days. Also, 22.3% of patients were readmitted within 30 days, 33.3% were readmitted within 60 days, and 40.2% were readmitted within 90 days.
conclusionThe costs associated with hospitalization for Medicare beneficiaries with HF are substantial and are compounded by a high rate of readmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.